Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world.

Orladeyo (berotralstat) - BioCryst

http://www.ncbi.nlm.nih.gov/pubmed/41582175

François Laliberté; Lorena Lopez-Gonzalez; Mark Davis-Lorton; Meri LiVecchi; Patrick Gillard; Raffi Tachdjian; Ramya Ramasubramanian; Sandra Nestler-Parr; Sean D MacKnight; William R Lumry

Jan 26, 2026